GPC3-CAR-T Cells
/ BriSTAR Immunotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 14, 2022
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1 | N=12 | Suspended | Sponsor: Beijing Tsinghua Chang Gung Hospital | Not yet recruiting ➔ Suspended
CAR T-Cell Therapy • Trial suspension • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3
June 07, 2021
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1; N=12; Not yet recruiting; Sponsor: Beijing Tsinghua Chang Gung Hospital; Trial completion date: Nov 2022 ➔ Oct 2023; Initiation date: Aug 2020 ➔ Sep 2021; Trial primary completion date: Aug 2022 ➔ Jun 2023
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3
August 10, 2020
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1; N=12; Not yet recruiting; Sponsor: Beijing Tsinghua Chang Gung Hospital
Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1